²»Á¼Ñо¿Ëù

The award was presented at evening ceremony in central London.

The posters demonstrate the capability of opti-ox technology to create any human cell.

²»Á¼Ñо¿Ëù wins biotech of the year for the second time and CEO of the year for Mark Kotter.

The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.

²»Á¼Ñо¿Ëù appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.

The pledge is part of our mission to code cells for novel cures and to be a purpose led company.

Funding raised to accelerate and expand cell therapy pipeline.

Three world leaders in science and entrepreneurship appointed to ²»Á¼Ñо¿Ëù's Board of Directors.